Anakinra by Swedish Orphan Biovitrum for Hospital Acquired Pneumonia (HAP): Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Hospital Acquired Pneumonia (HAP).

Related Keywords

Russia ,Sweden ,Stockholm ,United States ,America ,Swedish ,Biovitrum Sobi ,Anakinra Kineret ,Globaldata Pharmaceutical Intelligence Center ,Swedish Orphan Biovitrum ,Hospital Acquired Pneumonia ,Phase Transition Success Rate Model ,Rheumatoid Arthritis ,Cryopyrin Associated Periodic Syndromes ,Neonatal Onset Multisystem Inflammatory Disease ,Chronic Infantile Neurological ,Articular Syndrome ,Muckle Wells Syndrome ,Familial Cold Autoinflammatory Syndrome ,Kawasaki Disease ,Still Disease ,Orphan Biovitrum ,Middle East ,North America ,Pharmaceutical Intelligence ,